Better Artificial Intelligence Stock: Nebius Group vs. Astera Labs

Nebius reported Q3 revenue up 355% year-over-year to $146.1M but incurred a Q3 net loss of $119.6M, massive Q3 capex of $955.5M (vs $172.1M prior) and exited Q3 with over $4.0B of debt, indicating heavy capital intensity and rising leverage. Astera Labs posted record Q3 revenue of $230.6M (up 104% y/y), a Q3 net income of $91.1M (vs a prior-year loss of $7.6M), Q4 revenue guidance of $245M–$253M, modest Q3 capex of $18.9M, and bolstered its product set with the aiXscale Photonics acquisition. Given Astera’s profitability, stronger margins, lower capex burden and a lower price-to-sales multiple versus Nebius, the piece concludes Astera is the more attractive investment despite strong top-line growth at Nebius.

Analysis

Market structure: Hyperscalers (MSFT, META) and AI component suppliers (ALAB, optical/PCIe vendors) are the primary winners; capital-intensive data‑center builders like NBIS win short‑term revenue but lose margin and credit quality. Nebius’ Q3 capex of $955.5m and >$4bn debt versus ALAB’s $18.9m capex and $91.1m Q3 net income create diverging capital structures that will shift pricing power to profitable, low‑capex suppliers. Expect supplier pricing power and ASPs for high‑speed optics/interconnects to stay elevated through 2026 as AI infra spend ramps from $59b (2025) toward the $356b 2032 forecast.

Risk assessment: Tail risks include a large customer pullback (20–30% cutback by a hyperscaler), regulatory export/AI model limits, or a US dollar spike tightening offshore financing—each could vaporize projected demand and strain Nebius’ refinancing ability within 6–18 months. Short‑term (days/weeks) volatility will hinge on Q4 guidance and any debt raises; medium term (3–12 months) watch NBIS leverage ratios and covenant windows; long term (2–5 years) model efficiency or on‑chip acceleration could materially reduce compute per $ of revenue.

Trade implications: Implement a preference for ALAB (long 2–4% position) and avoid or short NBIS (size 1–2% or use options). Ideal pair trade: long ALAB equal‑dollar and short NBIS to neutralize sector beta; complement with ALAB 12–18 month call spreads (25–40% OTM) to capture upside while limiting premium. Rotate into semiconductor equipment and optical names, underweight high‑capex pure data‑center builders; enter on pullbacks of 10–20% or after Q4 prints, set tactical stops of 15–25%.

Contrarian angles: Consensus discounts NBIS too heavily on revenue momentum—if Nebius converts multiyear contracts into long duration, high‑margin renewals, downside is limited despite leverage; conversely, ALAB may already price a near‑term growth multiple that requires continued >2x YoY revenue beats. Historical cloud build cycles show suppliers (optics, interposers) often outperform operators once capacity saturates; unintended consequences include stranded assets and energy cost inflation that could compress NBIS cash flow and force dilutive raises within 12 months.

Key Decisions for Investors

• Establish a 2–4% long position in Astera Labs (ALAB) within 1–4 weeks, targeting 30–50% upside over 12 months; hedge with a 12–18 month 25–40% OTM call spread to limit premium outlay and sell half on a 30% gain.
• Initiate a tactical short or underweight NBIS (size 1–2%) via 3–6 month put spreads (buy 15–25% OTM puts, sell 5–10% nearer strikes) to profit from refinancing risk and potential multiple compression; cap risk with stop‑loss if NBIS issues convertible debt or announces >$1bn equity raise.
• Execute a pair trade: equal‑dollar long ALAB / short NBIS to neutralize macro beta, rebalance monthly and close if spread narrows by >20% or after 2 consecutive quarters of divergent operational metrics.
• Overweight optical/interconnect and semiconductor test/equipment suppliers by +3–5% of portfolio weight, underweight capital‑intensive data‑center operators and REITs by −3–5%; rotate on hyperscaler procurement announcements or a 50bp move in US real yields which would meaningfully raise NBIS funding costs.